Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Prognostic value of glomerular hematuria in primary membranous nephropathy (PMN) patients with nephrotic syndrome (NS) has not been well understood. We investigated the earlier improvement of hematuria in PMN patients with NS receiving immunosuppressive (IS) therapies to illuminate its prediction capacity for the treatment response and remission status at 12 months.
This is a single-center retrospective study. From 1 January 2021 to 30 June 2024, patients with biopsy-proven PMN and NS starting IS therapy after renal biopsy were recruited. The main exposures were baseline hematuria and hematuria disappearing at 6 months. The outcomes was nephrotic remission status at 12 months. Binary logistic regression models were used to estimate the relationship between exposures and outcomes.
One hundred and twenty-seven patients met the eligibility criteria. One hundred and twelve patients (88.2%) had glomerular hematuria at the renal biopsy. Patients with hematuria had larger ages (57.2±12.4 vs 47.9±12.7, P=0.007), higher serum h-CRP levels (1.14 (0.66, 2.11) vs 0.41 (0, 0.91), P=0.004), and lower remission rate at 12 months (66/112 (58.9%) vs 13/15 (86.67%), P=0.037). In the subgroup of patients with glomerular hematuria, baseline hematuria leves were 18 (8, 25) RBC/μl. No significant correlations were found between baseline hematuria levels and other clinical indexes. At 6 months, 31 out of 112 (27.7%) patients had negative-conversion of hematuria, and they had lower baseline PLA2R Ab titer (43.6 (0, 78.2) vs 67.5 (10.8, 191.4), P=0.025) and higher nephrotic remission rates at 12 months (26/31 (83.9%) vs 40/81 (49.4%), P=0.037), compared with those without. There were no significant differences in among IS agents between the groups. Binary logistic regression demonstrated that hematuria disappearance at 6 months was an independent predictor for nephrotic remission at 12 months (OR=0.211, 95%CI: 0.070-0.635, P=0.006).
Patients with PMN and NS have high prevalence of glomerular hematuria. Patients without hematuria or negative-conversion of hematuria at 6 months after IS treatment have higher nephrotic remission rates at 12 months. For patients with hematuria, hematuria disappearance at 6 months was an independent predictor for nephrotic remission at 12 months.
